In8Bio (INAB) Other financing activities (2021 - 2025)
In8Bio (INAB) posted Other financing activities of $18.1 million for Q4 2025, up 1307.06% sequentially from -$1.5 million in Q3 2025, and up 684.33% YoY from $2.3 million in Q4 2024.
In8Bio (INAB) Other financing activities (2021 - 2025) Analysis & Trends
In8Bio has reported Other financing activities for 5 years, with the latest figure at $18.1 million in Q4 2025.
- Quarterly Other financing activities rose 684.33% year-over-year to $18.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 178.31% YoY) and the FY2025 annual result came in at $18.5 million, up 201.96% from the prior year.
- Other financing activities advanced to $18.1 million in Q4 2025 per INAB's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Other financing activities peaked at $18.1 million in Q4 2025 and troughed at -$36.3 million in Q4 2021.
- A 5-year average of -$2.0 million and a median of $1.5 million in 2025 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 684.33% in 2025, down 139.32% in 2025.
- Over 5 years, Other financing activities stood at -$36.3 million in 2021, then soared by 73.83% to -$9.5 million in 2022, then soared by 134.51% to $3.3 million in 2023, then slipped by 29.53% to $2.3 million in 2024, then surged by 684.33% to $18.1 million in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $18.1 million, -$1.5 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.12 Mn |
| Dec 31, 2025 | 18.12 Mn |
| Sep 30, 2025 | -1.50 Mn |
| Sep 30, 2025 | -1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 383,000.00 |
| Mar 31, 2025 | 383,000.00 |
| Dec 31, 2024 | 2.31 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Dec 31, 2023 | 3.28 Mn |
| Dec 31, 2023 | 3.28 Mn |
| Dec 31, 2022 | -9.50 Mn |
| Dec 31, 2022 | -9.50 Mn |
| Dec 31, 2021 | -36.30 Mn |
| Dec 31, 2021 | -36.30 Mn |